Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Nicole R GrieselhuberAlice S MimsPublished in: Current hematologic malignancy reports (2021)
The DOT1L inhibitor pinometostat in KMT2A-rearranged AML, the menin inhibitors KO-539 and SYNDX-5613 in KMT2Ar and NPM1-mutated AML, and the mutant TP53 inhibitor APR-246 are examples of novel agents targeting specific mutations in AML. In addition, BET inhibitors, polo-like kinase inhibitors, and MDM2 inhibitors are promising new drug classes for AML which do not depend on the presence of a particular mutation. AML remains in incurable disease for many patients but advances in genomics, epigenetics, and drug discovery have led to the development of many potential novel therapeutic agents, many of which are being investigated in ongoing clinical trials. Additional studies will be necessary to determine how best to incorporate these novel agents into routine clinical treatment of AML.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- clinical trial
- drug discovery
- end stage renal disease
- cancer therapy
- randomized controlled trial
- chronic kidney disease
- ejection fraction
- emergency department
- peritoneal dialysis
- risk assessment
- drug delivery
- clinical practice
- climate change
- atomic force microscopy
- wild type
- smoking cessation
- adverse drug
- single molecule
- phase iii
- drug induced